Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Camrelizumab + Apatinib in Oral Squamous Cell Carcinoma
NCT05069857Phase 2Recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Sep 2021
- Primary completion
- Aug 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in oral squamous cell carcinoma (OSCC), sponsored by Shanghai Jiao Tong University School of Medicine. Started Sep 2021; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT05069857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05069857.